Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acarovac MPL
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Acarovac MPL is a next-generation subcutaneous immunotherapy (SCIT) product designed for the treatment of house dust mite (HDM)-induced allergic rhinoconjunctivitis and perennial allergic rhinitis. It contains allergoids derived from Dermatophagoides pteronyssinus and Dermatophagoides farinae (house dust mites), which are chemically modified allergens to reduce allergenicity while maintaining immunogenicity. These allergoids are adsorbed onto an adjuvant system composed of microcrystalline tyrosine (MCT), a biodegradable depot, and monophosphoryl lipid A (MPL), an immune response modulator. The combination aims to enhance safety, efficacy, and patient compliance by enabling ultra-short course therapy with fewer injections compared to traditional regimens. The mechanism involves immunomodulation—shifting the immune response away from allergy-promoting pathways by increasing specific immunoglobulins and reducing interleukin-4 levels[1][2][3][4][5][6][8].
- Brand names
- Acarovac MPLAcarovac Quattro
- Other names
- Acarovac MPL
02
Targets
TCR (T cell antigen receptor complex)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on Acarovac MPL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acarovac MPL.